Innovent Biologics
Address: 168 Dongping Street,, Suzhou Industrial Park, Suzhou, Jiangsu. 215123,About Us
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically.
Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.
Sectors
- Collaborations & Partnerships-Manufacture
- Contract Research & Development
- Proprietary Research & Manufacture
- Generic Formulations
- Collaborations & Partnerships- R&D
Categories
- Finished Dosage
- Biotechnology
- Clinical Development-Pipeline
- Antibodies-monoclonals
- BioPharmaceuticals
- Biosimilars
- New Drug Applications
- Generic Formulations
- Antibody Drug Conjugates
- Licensing
- Autoimmune Products
- Immunotherapy
- immuno-oncology
- Platform Technology-Drug Discovery
News
Innovent Biologics and Eli Lilly have entered into a global strategic collaboration
Under the terms of the strategic collaboration, Innovent is expected to lead programs from discovery through clinical proof of concept in China, leveraging its antibody technology platforms and clinical development capabilities.2 As part of the collaboration, Lilly will receive exclusive rights to develop and commercialize the resulting medicines worldwide outside of Greater China, while Innovent retains rights within the region.
Innovent is set to receive a $350 million upfront payment and will be eligible for development, regulatory, and commercial milestone payments totaling up to approximately $8.5 billion, contingent on future achievements. The company will also be eligible for tiered royalties on net sales outside Greater China.2
Innovent Biologics and Roche Enter into Exclusive Global License Agreement for Next-Generation DLL3 Antibody-Drug Conjugates
San Francisco, USA and Suzhou, China, January 2, 2025 - Innovent Biologics, Inc. (HKEX: 01801) ("Innovent"), a biopharmaceutical company dedicated to developing, manufacturing and commercializing innovative medicines for major disease areas such as oncology, autoimmunity, cardiovascular and metabolic, and ophthalmology, today announced that it has entered into an exclusive global collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to advance the development of IBI3009, a next-generation antibody-drug conjugate (ADC) candidate targeting Delta-like ligand 3 (DLL3), to provide a new treatment option for patients with advanced small cell lung cancer (SCLC). IBI3009 has received IND approval in Australia, China and the United States, and the first patient was dosed in a Phase I clinical study in December 2024.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com